Posters

Ranibizumab for the complex treatment of neovascular glaucoma in patients with proliferative diabetic retinopathy

Poster Details

First Author: T.Zimina UKRAINE

Co Author(s):    I. Pastukh   A. Mezentseva           

Abstract Details

Purpose:

To present and analyze results of intravitreal (IVT) ranibizumab (Lucentis) for the complex treatment of neovascular glaucoma (NG) in patients with proliferative diabetic retinopathy (PDR)

Setting:

Kharkiv City Clinical Hospital № 14 named after prof. L.L. Girshman, Ukraine; Ophthalmology Department, Kharkov Medical Academy of Postgraduate Education, Ukraine

Methods:

Two adult patients (3 eyes) with NG and PDR were assigned to receive 2 monthly IVT injections of 0.5 mg ranibizumab. 1 week after first injection Trabeculectomy was performed and intraocular pressure (IOP) decreased. 1 week after second injection Phacoemulsification with intraocular lens (IOL) implantation was performed. After 3-4 weeks retinal laser coagulation performed for all eyes. Assessment of visual acuity changes was the percentage of patients gaining of best-corrected visual acuity (BCVA); the central retinal thickness (CRT) measured by optical coherence tomography (OCT); tonometry, biomicroscopy, fundus photographs, and fluorescein angiography were evaluated.

Results:

1 week after first IVT ranibizumab injection iris neovascularisation decreased and Trabeculectomy was performed. IOP become 15-16 mm Hg. 1 week after second ranibizumab injection Phacoemulsification with intraocular lens (IOL) implantation was performed. After 2 months of follow-up all patients gained BCVA; mean BCVA improved on 10-15%. CRT showed a mean decrease of 45-55%. IOP was normal. These gave opportunity to start retinal laser coagulation for all eyes. After 6 and 12 months of follow-up BCVA and IOP remained steady. Term of observation is one year.

Conclusions:

Ranibizumab is generally well-tolerated in complex treatment of neovascular glaucoma in patients with proliferative diabetic retinopathy. It gives opportunity to decrease iris neovascularisation, CRT, and perform surgery with retinal laser coagulation. FINANCIAL INTEREST: NONE